
1. Summary of the Week
From November 14 to 20, a total of 25 biopharmaceutical licensing and collaboration transactions were announced globally. Of these, 6 were China-related, defined as transactions involving at least one China-based company. These comprised five out-licensing deals and one domestic partnership.
In China, the largest transaction involved Starna Therapeutics and Pfizer for the three preclinical investigational in vivo CAR-T programs targeting autoimmune diseases, with an upfront payment of $330 million and a total deal value of $2.6 billion.
Outside China, 19 deals were announced. The largest transaction involved a strategic collaboration between DISCO Pharmaceuticals and AbbVie to advance novel AND-gated bispecific therapeutics for solid tumors. The agreement includes an upfront payment of $40 million, with eligibility for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales.
2026年11月14-20日,全球医药市场共签署了25项资产授权和合作协议。中国市场共达成6项交易,包括5项出海交易和1项国内交易。
中国市场,本周最大的交易是星锐医药与Pfizer就三款处于IND申报前阶段、用于治疗自身免疫性疾病的 in vivo CAR-T项目达成海外独家许可协议,首付款3.3亿美元,总金额可达26亿美元。
中国以外市场,本周共签署了19项资产授权和合作协议。最大的交易是DISCO Pharmaceuticals与AbbVie达成战略合作和许可协议,以发现和开发新的用于治疗实体瘤的AND门控双特异性疗法,首付款4000万美元,期权、开发和其他里程碑付款可达25亿美元,以及全球净销售额的分层特许权使用费。
2. Licensing Deals
| Deal Type | Licensor | Licensee | Assets | Disease | Stage | Total amount ($ million) |
Upfront ($ million) |
Deal Territory |
|---|---|---|---|---|---|---|---|---|
| China OL |
Starna Therapeutics 星锐医药 |
Pfizer | Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology; another compound; CAR-T program 3; CAR-T program 2; STR-P006 | Autoimmune Disease | Pre-Clinical | 2,630 | 330 | United States; Europe; Japan; Chinese Mainland; Hong Kong, Macao and Taiwan; Global |
| China OL |
InnoGen 银诺医药 |
Arcera | efsubaglutide alfa | Metabolic Dysfunction-Associated Steatohepatitis (MASH); Polycystic Ovary Syndrome (PCOS); Overweight; Type 2 Diabetes; Obstructive Sleep Apnea (OSA); Diabetes; Obesity | Approved | 1,000 | 15 | Other |
| China OL |
Longuide 厚存纳米 |
Undisclosed | LNP technology platform | Undisclosed | Undisclosed | Undisclosed | Undisclosed | Global |
| China OL |
Betta Pharmaceuticals 贝达药业 |
Mankind Pharma | ensartinib | Hematology; Rare Diseases; Oncology; Rare Diseases | Approved | Undisclosed | Undisclosed | Other |
| China OL |
Delonix Bioworks 羽冠生物 |
A*STAR | OMV-based Klebsiella pneumoniae vaccine | Klebsiella Infection | Pre-Clinical | Undisclosed | Undisclosed | Global |
| China Domestic |
Ditu Zhiyuan 迪途智源 |
Hanx Biopharmaceutical 翰思艾泰 |
Research Collaboration on the Meritudio BioAI Platform | Oncology | Undisclosed | Undisclosed | Undisclosed | Global |
2a. China Section


3. M&A Deals
| Status | Acquiree | Acquiror | Acquisition Type | Item | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| Proposed | Ollin Biosciences | Johnson & Johnson | Full Acquisition | IBI324 | 3,325 | 2,200 |
| Proposed | Calytrix Bio | Eli Lilly | Full Acquisition | biparatopic antibody | 1,500 | Undisclosed |
| Proposed | Mayne Pharma | Richter Group | Full Acquisition | estetrol+drospirenone | 390 | Undisclosed |
| Proposed | Aytu BioPharma | Rosemont | Full Acquisition | gepirone | Undisclosed | Undisclosed |
4. Top Deals of 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-10-22 | Peptidstar Therapeutics 瀚辰星泰 |
Gilead Sciences | Gastroenterology; Immunology; Dermatology | Phase I | Undisclosed | 1,275 |
| 2026-01-30 | CSPC Pharma 石药集团 |
AstraZeneca | Endocrine & Metabolic | IND; Pre-Clinical | 18,500 | 1,200 |
| 2026-05-29 | Innovent Biologics 信达生物 |
Pfizer | Oncology | Pre-Clinical | 10,500 | 650 |
| 2026-01-13 | RemeGen 荣昌生物 |
Abbvie | Rare Disease; Oncology | Phase II | 5,600 | 650 |
| 2026-05-12 | Hengrui Pharmaceuticals 恒瑞医药 |
Bristol-Myers Squibb | Haematology; Oncology | Pre-Clinical | 15,200 | 600 |
| 2026-07-14 | Dizal Pharma 迪哲医药 |
AstraZeneca | Haematology; Oncology; Rare Diseases | Approved | 1,500 | 600 |
| 2026-10-02 | Abogen Biosciences 艾博生物 |
Novartis | Undisclosed | Undisclosed | 7,775 | 575 |
| 2026-10-19 | Hansoh Pharmaceutical 豪森药业 |
Roche | Undisclosed | Pre-Clinical | 15,510 | 400 |
| 2026-09-28 | SciBrunch Therapeutics 思璞锐 |
Merck & Co. | Oncology | Pre-Clinical | 2,130 | 400 |
| 2026-11-04 | Sino Biopharmaceutical 中国生物制药 |
Boehringer Ingelheim | Undisclosed | Pre-Clinical | 7,000 | 358 |
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-07-21 | TYK medicines 同源康医药 |
Qilu Pharmaceutical 齐鲁制药 |
Oncology | Filed | 384 | 42 |
| 2026-05-29 | Genrix Bio 智翔金泰 |
YaoPharma 药友制药 |
Hematology; Rare Diseases; Immunology; Dermatology; Oncology | Filed | 253 | 42 |
| 2026-03-23 | Corxel Pharmaceuticals 箕星药业 |
Everest Medicines 云顶新耀 |
Cardiovascular | Approved | 50 | 30 |
| 2026-02-05 | Micot Technology 麦科奥特 |
Everest Medicines 云顶新耀 |
Genitourinary; Endocrine & Metabolic | Phase III | 172.48 | 27.82 |
| 2026-01-17 | Raynovent 众生药业 |
Qilu Pharmaceutical 齐鲁制药 |
Gastroenterology; Respiratory; Endocrine & Metabolic | Phase III | 139.10 | 27.82 |
| 2026-04-28 | Huahui Health 华辉安健 |
BeOne Medicines 百济神州 |
Oncology | Pre-Clinical | 2,024 | 20 |
| 2026-01-12 | Wan Bang De 万邦德 |
Hisoar Pharmaceutical 海翔药业 |
Neurology; Rare Disease | Pre-Clinical | 20.87 | 16.69 |
| 2026-01-06 | Accendatech 尚德药缘 |
Yifan Pharmaceutical 亿帆医药 |
Neurology; Ophthalmology; Respiratory; Hematology; Rare Disease; Immunology; Oncology | Phase III | 20.87 | 13.91 |
| 2026-02-04 | Akeso Biopharma; Kangrong Dongfang 康方生物 |
Jumpcan Pharmaceutical 济川药业 |
Rare Disease; Cardiovascular | Approved | 12.52 | 11.13 |
| 2026-01-20 | Insilico Medicine 英矽智能 |
Hengtai Biotechnology 衡泰生物 |
Neurology | Pre-Clinical | 66 | 10 |
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-03-20 | Synnovation Therapeutics | Novartis | Oncology | Phase I/II | 3,000 | 2,000 |
| 2026-06-01 | Edgewise Therapeutics | Servier | Musculoskeletal; Rare Diseases | Phase II | 2,650 | 1,550 |
| 2026-10-01 | Regeneron | Sanofi | Immunology | Phase I | 8,000 | 1,000 |
| 2026-06-08 | Nurix Therapeutics | Roche | Haematology; Rare Diseases; Immunology; Oncology | Phase III | 2,300 | 700 |
| 2026-03-19 | Corium Therapeutics | Collegium Pharmaceutical | Psychiatry | Approved | 785 | 650 |
| 2026-08-26 | Biohaven | SK Biopharmaceuticals | Neurology | Phase II/III | 795 | 400 |
| 2026-10-04 | Alentis Therapeutics | CSL | Respiratory; Gastroenterology; Immunology; Rare Diseases; Oncology; Genitourinary | Phase II | 1,555 | 355 |
| 2026-07-29 | Sail Biomedicines | Johnson & Johnson | Immunology | Pre-Clinical | 925 | 320 |
| 2026-03-09 | GSK | Alfasigma | Gastroenterology; Rare Disease; Dermatology; Endocrine & Metabolic | Filed | 690 | 300 |
| 2026-02-23 | Vir Biotechnology | Astellas Pharma | Oncology | Phase I/II | 1,705 | 240 |
5. 2021-2025 China Innovative Drug Licensing Transactions
About YAFO Capital
YAFO Capital is a global boutique investment and BD advisory firm with professional teams across China, the U.S., Europe, and Southeast Asia. Our expertise spans four core business segments: transaction advisory and consulting, NewCo incubation, investment management, and partnering forums. Over the past 12 years, YAFO has built a strong track record, closing dozens of business development transactions with leading global pharmaceutical and biotech companies. For more information, please visit www.yafocapital.com.
关于雅法资本
雅法致力于生物医药项目的跨境及国内授权交易、成立NewCo和并购交易。基于雅法在全球广泛的人脉与资源网络,在过去十二年成功推进了大量的海外项目进入中国市场并协助诸多中国产品完成海外授权。雅法拥有经验丰富的全球交易团队,覆盖美国、日本、欧洲等全球主要医药创新区域。核心合伙人背景多元化,包括华尔街资深投行交易经验及跨国药企经历,为客户交易提供全方位的强力支持。
